|Bid||163.80 x 900|
|Ask||164.90 x 1100|
|Day's range||161.62 - 165.48|
|52-week range||152.04 - 327.78|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||68.07|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Veeva Systems (NYSE: VEEV) today announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns. Veeva Crossix HCP Trigger Data connects consumers' engagement with a brand's website to their healthcare professional (HCP) visits. Veeva Crossix Omnichannel Boost provides a holistic view of HCP and patient engagement across field and promotional channels.
Veeva Systems (NYSE: VEEV) today announced Batavia Biosciences selected Veeva Vault Quality Suite to optimize its global quality assurance (QA), unifying content, processes, and training management on a single platform. Batavia Biosciences will also benefit from real-time insights that support ongoing QA improvements and inspection readiness.
Veeva Systems (NYSE: VEEV) today announced that visionaries from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK will be keynote speakers at the 2022 Veeva R&D and Quality Summit on Oct.19 and 20 in Boston. Speakers will showcase how innovations and advancements in clinical, quality, regulatory, and safety enable greater efficiency and speed across the product lifecycle.